trending Market Intelligence /marketintelligence/en/news-insights/trending/AjxXqWFRYX7hqgHwhwydzQ2 content esgSubNav
In This List

Aeterna Zentaris drug gains EU approval to diagnose growth hormone deficiency


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Aeterna Zentaris drug gains EU approval to diagnose growth hormone deficiency

The European Medicines Agency granted marketing approval to Aeterna Zentaris Inc.'s macimorelin for the diagnosis of adult growth hormone deficiency.

Adult growth hormone deficiency, or AGHD, occurs when the body's anterior pituitary gland does not produce enough growth hormone. This stimulates the release of another hormone called insulin-like growth factor 1, which is mainly produced by the liver. Together, these hormones produce growth in childhood and adult life.

AGHD may occur in adults with a history of childhood-onset growth hormone deficiency or during adulthood as an acquired condition. About 35,000 adults could be afflicted with growth hormone deficiency, said Aeterna in its Jan. 16 press release.

The Summerville, S.C.-based biopharmaceutical company said trials showed that macimorelin, which stimulates the secretion of growth hormone from the pituitary gland into the circulatory system, was safer and simpler to administer than the current methods of testing for insulin-induced hypoglycemia, or low blood sugar levels. The medicine was also well-tolerated by patients and reliable in diagnosing the condition.

In November 2018, the Committee for Medicinal Products for Human Use recommended granting a marketing authorization to macimorelin, which is marketed in the U.S. as Macrilen, for diagnosing AGHD.

Strongbridge Biopharma PLC sold the U.S. and Canada rights to Macrilen to Novo Nordisk A/S, which it had acquired from Aeterna, in December 2018.